All In Biotech

Drug Trial Radar · NCT00074581

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples

Last checked: Nov 19, 2026Latest source record: Nov 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,526 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,526

Actual

Start

Feb 2005

Primary completion

May 2015

Study completion May 2015

Sponsor

Sponsor type
NIH
Collaborators
HIV Prevention Trials Network
First posted
Dec 17, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.

Conditions

  • HIV Infections

Interventions

  • AtazanavirDrug

    300 mg taken orally once daily

  • DidanosineDrug

    400 mg taken orally once daily

  • EfavirenzDrug

    600 mg taken orally once daily

  • Emtricitabine/Tenofovir disoproxil fumarateDrug

    200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily

  • LamivudineDrug

    300 mg taken orally once daily

  • Lopinavir/RitonavirDrug

    200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily

  • NevirapineDrug

    200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily

  • StavudineDrug

    Dosage depends on weight

  • Tenofovir disoproxil fumarateDrug

    300 mg taken orally once daily

  • Zidovudine/LamivudineDrug

    150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Linked Partner HIV Infection Rates in Early-ART and Delayed-ART ArmsTime frame: Throughout study
  2. All Partner HIV Infection Rates in Early-ART and Delayed-ART ArmsTime frame: Throughout study

Locations

17 sites in 9 countries. Site status is shown where the registry gives one.

  • Fenway Community Health Ctr. CRS

    Boston, Massachusetts

  • Gaborone CRS

    Gaborone, Botswana

  • HSE-Hospital dos Servidores do Estado CRS

    Rio de Janeiro, Brazil

  • Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

    Rio de Janeiro, Brazil

  • Hospital Geral de Nova Iguaçu CRS (HGNI CRS)

    Nova Iguaçu, Rio de Janeiro, Brazil

  • Hospital Nossa Senhora da Conceicao CRS

    Port Alegre, Rio Grande do Sul, Brazil

  • NARI Clinic at Gadikhana Dr. Kotnis Municipal Dispensary CRS

    Pune, Maharashtra, India

  • NARI Clinic at NIV CRS

    Pune, Maharashtra, India

  • NARI Pune CRS

    Pune, Maharashtra, India

  • Chennai Antiviral Research and Treatment (CART) CRS

    Chennai, Tamil Nadu, India

  • Kisumu Crs

    Kisumu, Nyanza, Kenya

  • Blantyre CRS

    Blantyre, Malawi

  • Malawi CRS

    Lilongwe, Malawi

  • Soweto HPTN CRS

    Johannesburg, Gauteng, South Africa

  • Wits Helen Joseph Hospital CRS (Wits HJH CRS)

    Johannesburg, Gauteng, South Africa

  • CMU HIV Prevention CRS

    Chiang Mai, Thailand

  • Parirenyatwa CRS

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.